Bruker Corporation $BRKR Shares Sold by Alyeska Investment Group L.P.

Key Points

• Alyeska Investment Group L.P. significantly reduced its stake in Bruker Corporation by selling 1,162,958 shares, resulting in ownership of just 325,000 shares, which represents a decrease of 78.2%.
• The company's latest earnings report showed a miss on EPS, with $0.32 reported compared to analysts' expectations of $0.33, alongside a slight year-over-year revenue decline of 0.4%.
• Bruker Corporation announced a quarterly dividend of $0.05 per share, which will be paid on October 3rd, representing an annualized dividend yield of 0.7%.

Alyeska Investment Group L.P. cut its holdings in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 78.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 325,000 shares of the medical research company's stock after selling 1,162,958 shares during the quarter. Alyeska Investment Group L.P. owned 0.21% of Bruker worth $13,566,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Vestal Point Capital LP purchased a new stake in Bruker during the 1st quarter worth about $12,522,000. Dark Forest Capital Management LP purchased a new stake in shares of Bruker in the 1st quarter valued at approximately $4,296,000. VeriStar Capital Management LP acquired a new stake in shares of Bruker in the 1st quarter valued at $3,473,000. Focus Partners Advisor Solutions LLC purchased a new stake in shares of Bruker during the 1st quarter worth $332,000. Finally, Royal Bank of Canada lifted its position in shares of Bruker by 8.3% during the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock worth $5,148,000 after purchasing an additional 9,501 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Wall Street Analyst Weigh In

BRKR has been the topic of several recent analyst reports. Barclays dropped their target price on Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Monday, August 4th. Bank of America dropped their price objective on Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Citigroup decreased their target price on Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a research note on Monday, August 4th. Wells Fargo & Company lowered their price target on Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a report on Tuesday, August 5th. Finally, Stifel Nicolaus set a $40.00 price objective on shares of Bruker and gave the stock a "hold" rating in a report on Tuesday, August 5th. Five research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $51.30.

Bruker Stock Performance

Shares of NASDAQ BRKR traded up $1.04 during trading hours on Friday, reaching $30.83. The stock had a trading volume of 8,539,948 shares, compared to its average volume of 4,029,705. The firm has a 50-day moving average of $37.12 and a 200-day moving average of $39.51. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of 59.29, a PEG ratio of 3.84 and a beta of 1.22. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $72.94.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The company's quarterly revenue was down .4% on a year-over-year basis. During the same period last year, the firm earned $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Equities research analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker's dividend payout ratio (DPR) is currently 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.